Neuroendocrine Peptide Catestatin Reduces Alzheimer's Tau Pathology and Amyloid Through Adrenergic Inhibition
Catestatin ameliorated tauopathy, amyloidogenesis, synaptic dysfunction, and neuroinflammation across AD, CBD, and PSP models through inhibition of adrenergic signaling.
Quick Facts
What This Study Found
CST ameliorated tauopathy, amyloidogenesis, synaptic dysfunction, and neuroinflammation in AD, CBD, and PSP models through adrenergic signaling inhibition — revealing catecholamine-tau pathology connection.
Key Numbers
How They Did This
In vitro and in vivo models of AD, CBD, and PSP treated with catestatin, with assessment of tau aggregation, amyloid pathology, synaptic markers, neuroinflammation, and adrenergic signaling.
Why This Research Matters
Tau pathology drives multiple neurodegenerative diseases with no effective treatment. Catestatin addresses tau through a novel mechanism (adrenergic inhibition) different from existing approaches.
The Bigger Picture
Catestatin connects two seemingly unrelated systems — stress hormones and neurodegenerative protein aggregation — opening an entirely new therapeutic approach to tauopathies.
What This Study Doesn't Tell Us
Preclinical models. Catestatin delivery to brain needs optimization. Chronic adrenergic inhibition may have cardiovascular effects.
Questions This Raises
- ?Would catestatin cross the BBB sufficiently for clinical use?
- ?Do beta-blockers (also adrenergic inhibitors) show similar tau reduction?
- ?Could catestatin prevent tauopathy onset in at-risk individuals?
Trust & Context
- Key Stat:
- Stress hormone → neurodegeneration Catestatin reveals that adrenergic (stress hormone) signaling drives tau pathology — and blocking it with this natural peptide reduces neurodegeneration across three diseases
- Evidence Grade:
- Multi-model preclinical study across three neurodegenerative diseases. Novel mechanistic insight.
- Study Age:
- Published in 2025.
- Original Title:
- Catestatin ameliorates tauopathy and amyloidogenesis via adrenergic inhibition.
- Published In:
- bioRxiv : the preprint server for biology (2026)
- Authors:
- Jati, Suborno, Kal, Satadeepa, Munoz-Mayorga, Daniel, Tang, Kechun, Sahoo, Debashis, Chen, Xu, Mahata, Sushil K
- Database ID:
- RPEP-15372
Evidence Hierarchy
Frequently Asked Questions
How does stress relate to Alzheimer's?
This study shows stress hormones (catecholamines) actively drive the tau protein aggregation that causes Alzheimer's and related diseases. The natural peptide catestatin blocks this pathway.
Could reducing stress prevent Alzheimer's?
While lifestyle stress management is always good, this study suggests pharmacological adrenergic blockade (not just relaxation) could prevent the molecular damage that leads to tau-based neurodegeneration.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15372APA
Jati, Suborno; Kal, Satadeepa; Munoz-Mayorga, Daniel; Tang, Kechun; Sahoo, Debashis; Chen, Xu; Mahata, Sushil K. (2026). Catestatin ameliorates tauopathy and amyloidogenesis via adrenergic inhibition.. bioRxiv : the preprint server for biology. https://doi.org/10.64898/2026.01.04.697519
MLA
Jati, Suborno, et al. "Catestatin ameliorates tauopathy and amyloidogenesis via adrenergic inhibition.." bioRxiv : the preprint server for biology, 2026. https://doi.org/10.64898/2026.01.04.697519
RethinkPeptides
RethinkPeptides Research Database. "Catestatin ameliorates tauopathy and amyloidogenesis via adr..." RPEP-15372. Retrieved from https://rethinkpeptides.com/research/jati-2026-catestatin-ameliorates-tauopathy-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.